2024
Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis
Fang X, Raval N, O’Dell R, Naganawa M, Mecca A, Chen M, van Dyck C, Carson R. Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis. Brain Communications 2024, 6: fcae107. PMID: 38601916, PMCID: PMC11004947, DOI: 10.1093/braincomms/fcae107.Peer-Reviewed Original ResearchMedial temporal brain regionsAlzheimer's diseaseTemporal brain regionsCognitive deficitsBrain regionsCognitive impairmentPostmortem studiesBinds to SV2ASynaptic densityReduction of synaptic densityIndependent component analysisSynaptic lossAlzheimerDeficitsImpairmentBrainNeocortexComponent analysisPrimary pathologySV2ASynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2023
Evaluation of a First PET Tracer Suitable for Imaging the Sigma‑2 Receptor in the Brain of Nonhuman Primates
Alluri S, Zheng M, Holden D, Zhang Y, Zhang L, Felchner Z, Li S, Ropchan J, Carson R, Jia H, Huang Y. Evaluation of a First PET Tracer Suitable for Imaging the Sigma‑2 Receptor in the Brain of Nonhuman Primates. Molecular Pharmaceutics 2023, 21: 194-200. PMID: 38013422, DOI: 10.1021/acs.molpharmaceut.3c00750.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseLimited brain uptakeNonhuman primate brainCentral nervous systemPotential therapeutic targetPositron emission tomography (PET) imagingEmission Tomography ImagingTransmembrane protein 97Sigma-2 receptorsFirst PET tracerBrain penetrantBrain uptakeTherapeutic targetNervous systemPrimate brainNeurological disordersPET tracersNonhuman primatesTomography imagingProtein 97CancerDiseaseBrainCell typesReceptors
2022
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
Naganawa M, Gallezot J, Finnema S, Maguire R, Mercier J, Nabulsi N, Kervyn S, Henry S, Nicolas J, Huang Y, Chen M, Hannestad J, Klitgaard H, Stockis A, Carson R. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A. EJNMMI Research 2022, 12: 71. PMID: 36346513, PMCID: PMC9643320, DOI: 10.1186/s13550-022-00944-5.Peer-Reviewed Original ResearchTime-activity curvesBrain entryDrug concentrationsNon-human primate brainAnti-seizure activitySynaptic vesicle glycoprotein 2APlasma drug concentrationsPrevious human studiesBackgroundAntiepileptic drugsHealthy subjectsBlood samplesHuman studiesLevetiracetamPrimate brainEmission tomography dataBrivaracetamDistribution volumeArterial input functionBrainDrug characteristicsPositron emission tomography dataDrug entryFree fractionDrugsKinetic parameters k1A 3D atlas of functional human brain energetic connectome based on neuropil distribution
Yu Y, Akif A, Herman P, Cao M, Rothman D, Carson R, Agarwal D, Evans A, Hyder F. A 3D atlas of functional human brain energetic connectome based on neuropil distribution. Cerebral Cortex 2022, 33: 3996-4012. PMID: 36104858, PMCID: PMC10068297, DOI: 10.1093/cercor/bhac322.Peer-Reviewed Original ResearchConceptsSynaptic densityCortical regionsHigher synapse densityHuman cortical circuitsFunctional imaging studiesCortical activity mapsVivo PET imagingNeuropil distributionGlucose oxidationSynapse densityCortical circuitsMetabolic rateSynaptic connectionsCortical energeticsImaging studiesHuman cortexPET imagingHistological stainingRecent evidenceCortexHuman brainBrainVoxel levelActivity ratesAtlasPET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging
Toyonaga T, Fesharaki-Zadeh A, Strittmatter SM, Carson RE, Cai Z. PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging. Frontiers In Neuroscience 2022, 16: 787404. PMID: 35345546, PMCID: PMC8957200, DOI: 10.3389/fnins.2022.787404.Peer-Reviewed Original ResearchAnimal modelsPET imaging studiesPET imagingImaging studiesSynaptic vesicle glycoprotein 2ADisease animal modelsOngoing clinical investigationsDifferent injection routesSynaptic densityClinical investigationPharmacological effectsRodent brainNovel interventionsInjection routeNeurodegenerative disordersNeuropsychiatric diseasesPET studiesBrainMultiple diseasesPET centersDiseaseInjectable volumeImagingSmaller brainsPET
2021
PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain
Smart K, Naganawa M, Baldassarri SR, Nabulsi N, Ropchan J, Najafzadeh S, Gao H, Navarro A, Barth V, Esterlis I, Cosgrove KP, Huang Y, Carson RE, Hillmer AT. PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. Cerebral Cortex 2021, 31: 2787-2798. PMID: 33442731, PMCID: PMC8355478, DOI: 10.1093/cercor/bhaa387.Peer-Reviewed Original ResearchConceptsACh concentrationHuman volunteersHigh ACh concentrationsMuscarinic antagonist scopolamineHealthy human volunteersHuman brainCholinergic receptorsNicotine challengeAntagonist scopolaminePreclinical studiesStriatal regionsPET scansEndogenous neurotransmittersNeuropsychiatric diseasesNonhuman primatesWhole-brain imagesDrug occupancyNicotinic ligandsClinical populationsBrainAcetylcholineDistinct functional rolesStriatumVolunteersFunctional role
2017
Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates
Hillmer AT, Holden D, Fowles K, Nabulsi N, West BL, Carson RE, Cosgrove KP. Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates. EJNMMI Research 2017, 7: 59. PMID: 28741281, PMCID: PMC5524658, DOI: 10.1186/s13550-017-0305-0.Peer-Reviewed Original ResearchBrain microgliaTranslocator proteinAcute lipopolysaccharide administrationArterial blood samplingPositron emission tomography (PET) imagingReceptor kinase inhibitorMicroglia changesLipopolysaccharide administrationNeuroimmune functionMicroglial depletionMicroglia dynamicsTSPO levelsBlood samplingPET studiesOne animalKinase inhibitorsTomography imagingBaselineConclusionsThese studiesBrainMicrogliaImaging paradigmMacaca mulattaPreliminary evidenceImportant target
2016
Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancySynthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain
Nabulsi N, Mercier J, Holden D, Carré S, Najafzadeh S, Vandergeten MC, Lin SF, Deo A, Price N, Wood M, Lara-Jaime T, Montel F, Laruelle M, Carson RE, Hannestad J, Huang Y. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. Journal Of Nuclear Medicine 2016, 57: 777-784. PMID: 26848175, DOI: 10.2967/jnumed.115.168179.Peer-Reviewed Original ResearchConceptsSynaptic vesicle glycoprotein 2AWhole-body biodistributionPET radiotracersNonhuman primatesDose-limiting organHigher free fractionGray matter regionsBaseline VTNondisplaceable distribution volumeAntiepileptic drugsVitro inhibition constantSynaptic densityPreclinical evaluationMonkey brainDistribution volumeArterial samplingEndocrine cellsRegional volumesMatter regionsRhesus macaquesPET tracersUCBFree fractionBrainTarget occupancy
2015
Measurement of Bmax and Kd with the Glycine Transporter 1 Radiotracer 18F-MK6577 using a Novel Multi-Infusion Paradigm
Xia Y, Zheng MQ, Holden D, Lin SF, Kapinos M, Ropchan J, Gallezot JD, Huang Y, Carson RE. Measurement of Bmax and Kd with the Glycine Transporter 1 Radiotracer 18F-MK6577 using a Novel Multi-Infusion Paradigm. Cerebrovascular And Brain Metabolism Reviews 2015, 35: 2001-2009. PMID: 26198176, PMCID: PMC4671121, DOI: 10.1038/jcbfm.2015.163.Peer-Reviewed Original ResearchConceptsGlycine transporter-1 inhibitorNew positron emission tomography radiotracerPositron emission tomography (PET) radiotracerPotential therapeutic agentNondisplaceable distribution volumeNMDA receptorsVivo affinityBaboon brainDistribution volumeBmax valuesTomography radiotracerTherapeutic agentsVivo KDBrainRank orderUnlabeled compoundsRadiotracerKdBrainstem
2003
Brain Uptake of the Acid Metabolites of F-18–Labeled WAY 100635 Analogs
Carson R, Wu Y, Lang L, Ma Y, Der M, Herscovitch P, Eckelman W. Brain Uptake of the Acid Metabolites of F-18–Labeled WAY 100635 Analogs. Cerebrovascular And Brain Metabolism Reviews 2003, 23: 249-260. DOI: 10.1097/00004647-200302000-00012.Peer-Reviewed Original ResearchBrain uptakePositron emission tomography studyArterial blood samplesEmission tomography studiesGray matter parametersPlasma free fractionLow specific bindingTime-activity dataBlood samplesTime-activity curvesAcid metabolitesVascular radioactivityRhesus monkeysTomography studyML/Free fractionTissue compartmentsBrainHuman dataHigh-performance liquid chromatography analysisPhysiologic modelDistribution volume VSpecific bindingDynamic positron emission tomography (PET) studiesLiquid chromatography analysis
2002
Brain Incorporation of [11C]Arachidonic Acid in Young Healthy Humans Measured With Positron Emission Tomography
Giovacchini G, Chang M, Channing M, Toczek M, Mason A, Bokde A, Connolly C, Vuong B, Ma Y, Der M, Doudet D, Herscovitch P, Eckelman W, Rapoport S, Carson R. Brain Incorporation of [11C]Arachidonic Acid in Young Healthy Humans Measured With Positron Emission Tomography. Cerebrovascular And Brain Metabolism Reviews 2002, 22: 1453-1462. DOI: 10.1097/00004647-200212000-00006.Peer-Reviewed Original ResearchPositron emission tomographyArachidonic acidBrain incorporationEmission tomographyHuman brainCerebral blood volumeYoung healthy humansYoung healthy adultsRole of AAVivo quantitative methodBrain radioactivityAwake ratsHealthy humansPharmacological activationBlood volumeRat studiesHealthy adultsWhite matterArterial input functionBrainPhospholipase A2Important second messengerSignal transductionTomographySecond messenger